Compare Amphastar Pharmaceuticals Inc (AMPH) vs GoPro Inc (GPRO) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

GoPro (GPRO) trades at $0.76, up 0.37% with neutral technical signals. The company faces severe financial distress with negative net income margins (-20.7%) and ROE (-236.05%), though valuation ratios appear low (P/E 4.56, P/S 0.2). Recent strategic review for potential sale and CEO's $20M financing provide near-term catalysts, but consecutive earnings misses and declining revenue ($652M in 2025) highlight operational challenges.

Outlook remains highly speculative with binary outcomes. The strategic sale process offers potential upside, but ongoing cash burn, negative equity, and competitive pressures present substantial downside risk. Analyst sentiment is mixed with 21% buy ratings, reflecting the company's precarious financial position and event-driven investment thesis.